NEW YORK (GenomeWeb) – Agilent Technologies has announced a co-marketing agreement with contract research organization PureHoney Technologies to develop new applications on the RapidFire 365 High-throughput Mass Spectrometry System.
Under the terms of the agreement, the partners will work both together and independently on new workflows for pharmaceutical-focused research, forensic toxicology, and metabolomics analysis. RapidFire technology provides label-free, high-throughput screening for several applications.
The partnership will "enhance application offerings, providing scientists with a greater range of capabilities to enhance the depth and speed of pharmaceutical research," Monty Benefiel, Agilent VP and mass spectrometry division general manager, said in a statement.
Financial and other terms of the deal were not disclosed.
As the original developers of the RapidFire platform, the team behind PureHoney enters the partnership with plenty of experience using the technology.
Agilent acquired the RapidFire platform as part of its 2011 Biocius Life Sciences acquisition. In 2013, Agilent signed an agreement to develop a commercial version of Applied Proteomics' colon polyp/adenoma panel on RapidFire and other Agilent mass spec platforms.